Astellas advances Phase 3 setidegrasib trial in KRAS G12D pancreatic cancer
Astellas Pharma Inc. is presenting updates for PADCEV with pembrolizumab and late-stage setidegrasib trials in KRAS G12D pancreatic and lung cancers at ESMO 2026.
Astellas Pharma Inc. is presenting updates for PADCEV with pembrolizumab and late-stage setidegrasib trials in KRAS G12D pancreatic and lung cancers at ESMO 2026.